Cite
HARVARD Citation
Bachert, C. et al. (2015). A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.. Clinical and translational allergy. 5 (4), p. 1. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bachert, C. et al. (2015). A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.. Clinical and translational allergy. 5 (4), p. 1. [Online].